GASTROESOPHAGEAL JUNCTION (GEJ) CANCER
Clinical trials for GASTROESOPHAGEAL JUNCTION (GEJ) CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION (GEJ) CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stomach cancer: experimental drug BHB810 enters human trials
Disease control Recruiting nowThis study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seein…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) CANCER
Phase: PHASE1, PHASE2 • Sponsor: BigHat Biosciences, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) CANCER
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC